Hemostemix Inc. (CVE:HEM – Get Free Report) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$0.06 and traded as low as C$0.06. Hemostemix shares last traded at C$0.06, with a volume of 19,782 shares changing hands.
Hemostemix Price Performance
The company has a quick ratio of 0.48, a current ratio of 0.24 and a debt-to-equity ratio of -66.09. The business has a fifty day moving average of C$0.06 and a 200 day moving average of C$0.07. The firm has a market cap of C$12.30 million, a P/E ratio of -3.00 and a beta of 0.21.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Further Reading
- Five stocks we like better than Hemostemix
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
